Reliability, validity and responsiveness to change of the Saint George'S Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis

Rheumatology (United Kingdom)

Volumn 54, Issue 8, 2015, Pages 1369-1379

  Wallace, Beth ^a   Kafaja, Suzanne ^b   Furst, Daniel E ^b   Berrocal, Veronica J ^c   Merkel, Peter A ^d   Seibold, James R ^e   Mayes, Maureen D ^f   Khanna, Dinesh ^g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Scleroderma Research Consultants   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Autoinflammatory conditions; Dyspnoea; Patient attitude to health; Patient reported outcomes; Quality of life; Respiratory; Scleroderma and related disorders; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; BREATHING; CONSTRUCT VALIDITY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INTERNAL CONSISTENCY; INTERSTITIAL LUNG DISEASE; LUNG CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE;

EID: 84939481098     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu456     Document Type: Article

References (50)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367: 1683-91.
2. Thombs BD, Jewett LR, Assassi S et al. New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). Clin Exp Rheumatol 2012;30(2 Suppl 71):S23-9.
3. Bassel M, Hudson M, Taillefer SS et al. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology 2011;50:762-7.
4. Baron M, Sutton E, Hudson M et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008;67:644-50.
5. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: an international metaanalysis of individual patient data. Am J Med 2005;118: 2-10.
6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66: 940-4.
7. Mathai SC, Hummers LK, Champion HC et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
8. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85(Suppl B): 25-31, discussion 3-7.
9. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
10. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999;116:1175-82.
11. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156(2 Pt 1):536-41.
12. Al-Shair K, Atherton GT, Kennedy D et al. Validity and reliability of the St. George's Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest 2013;144:623-31.
13. Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology 2007;46: 296-301.
14. Khanna D, Lovell DJ, Giannini E et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008;67: 703-9.
15. Khanna D, Distler O, Avouac J et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36:2356-61.
16. Wiese AB, Berrocal VJ, Furst DE et al. Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. Arthritis Care Res 2014;66:1731-9.
17. Gladue H, Furst DE, Berrocal V et al. Comparison of baseline characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) cohort to patients enrolled in clinical trials of diffuse systemic sclerosis. American College of Rheumatology Annual Meeting. Washington, DC. November 12, 2012.
18. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
19. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46: 2410-20.
20. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
21. Clements PJ, Wong WK, Hurwitz EL et al. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80.
22. Khanna D, Clements PJ, Furst DE et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
23. Ware JE, Kosinski M, Keller SK. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA, USA: Health Institute, Tufts Medical Center, 1994.
24. Ware J. SF-36 health survey update. Spine (Phila Pa 1976) 2000;25:3130-9.
25. Khanna D, Furst DE, Clements PJ et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40.
26. Villalba WO, Sampaio-Barros PD, Pereira MC et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131: 217-22.
27. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
28. Wanger J, Clausen JL, Coates A et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26: 511-22.
29. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011;139:52-9.
30. Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26: 948-68.
31. Wells AU, Hansell DM, Corrin B et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992;47:738-42.
32. Moore OA, Goh N, Corte T et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosisrelated interstitial lung disease. Rheumatology 2013;52: 155-60.
33. Goldin J, ElashoffR, Kim HJ et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009;136:1333-40.
34. Ferrer M, Villasante C, Alonso J et al. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 2002;19:405-13.
35. Hays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res 1992;1:73-5.
36. Miller M. Coefficient alpha: a basic introduction from the perspectives of classical test theory and structural equation modeling. Struct Equation Model 1995;2: 255-73.
37. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ, USA: Erlbaum, 1988.
38. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
39. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64.
40. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995;108:305-10.
41. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
42. Celebi Sozener Z, Karabiyikoglu G, Duzgun N. Evaluation of the functional parameters in scleroderma cases with pulmonary involvement. Tuberk Toraks 2010;58: 235-41.
43. Matucci-Cerinic M, D'Angelo S, Denton CP, Vlachoyiannopoulos P, Silver R. Assessment of lung involvement. Clin Exp Rheumatol 2003;21(3 Suppl 29): S19-23.
44. de Oliveira NC, dos Santos Sabbag LM, Ueno LM et al. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement. Scand J Rheumatol 2007; 36:458-61.
45. Schoindre Y, Meune C, Dinh-Xuan AT et al. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009;36: 1481-5.
46. Merkel PA, Clements PJ, Reveille JD et al. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
47. Avouac J, Kowal-Bielecka O, Pittrow D et al. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis 2010;69:1360-3.
48. Tashkin DP, ElashoffR, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
49. Prosch H, Schaefer-Prokop CM, Eisenhuber E, Kienzl D, Herold CJ. CT protocols in interstitial lung diseases-a survey among members of the European Society of Thoracic Imaging and a review of the literature. Eur Radiol 2013;23:1553-63.
50. Saketkoo LA, Mittoo S, Huscher D et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014;69: 436-44.